Market cap
$66 Mln
Revenue (TTM)
$30 Mln
P/E Ratio
--
P/B Ratio
0.5
Div. Yield
0 %
Key Ratios and Highlights
| Growth Score (%) | Quarterly | Annual (TTM) | |||
|---|---|---|---|---|---|
| Particulars | QoQ | YoY | 1-Year | 3-Years | 5-Years |
| Revenue | -- | -- | -1.79 | -8.67 | -10.72 |
| EBIT | -11.12 | 11.27 | -40.84 | -207.95 | -226.38 |
| Net Profit | -53.47 | -23.43 | -53.69 | -223.76 | -235.64 |
| EPS | -35.66 | 1.65 | -19.54 | -37.14 | -9.72 |
| Book Value | -- | -- | -39.79 | -8.78 | -- |
| Key Ratios (%) | Average | Annual (TTM) | |||
|---|---|---|---|---|---|
| Particulars | 3-Years | 5-Years | TTM | Dec-22 | Dec-21 |
| EBIT-Margin
| -995.44 | -675.04 | -286.42 | -206.23 | -2,828.92 |
| Net Margin
| -2,878.02 | -2,878.02 | -294.71 | -- | -2,878.02 |
| Return on equity
| -21.17 | -29.13 | -136.99 | -61.52 | -57.86 |
| Return on Capital
| -13.47 | -22.71 | -- | -40.11 | -41.69 |
| Return on Assets
| -14.06 | -16.40 | -63.40 | -37.24 | -38.95 |
| Debt to Equity (x)
| -- | -- | 0.00 | 0.60 | 0.48 |
Profitability
ROCE
--
--
Earning before interest and taxes / (Average net worth + Average total Debt) * 100
|
Company Name
|
TTM
|
Dec-22
|
Dec-21
|
Dec-20
|
Dec-19
|
|---|---|---|---|---|---|
|
Surface Oncology (SURF)
|
--
|
-40.11
|
-41.69
|
41.39
|
-57.44
|
|
Peer Median
|
--
|
--
|
--
|
--
|
--
|
ROE
-136.99
Lower than Peers by 96.70
Profit after tax / Average Net worth * 100
|
Company Name
|
TTM
|
Dec-22
|
Dec-21
|
Dec-20
|
Dec-19
|
|---|---|---|---|---|---|
|
Surface Oncology (SURF)
|
-136.99
|
-61.52
|
-57.86
|
55.87
|
-66.45
|
|
Peer Median
|
-40.29
|
--
|
--
|
--
|
--
|
ROA
-63.40
Lower than Peers by 32.57
Profit after tax / Average Total assets * 100
|
Company Name
|
TTM
|
Dec-22
|
Dec-21
|
Dec-20
|
Dec-19
|
|---|---|---|---|---|---|
|
Surface Oncology (SURF)
|
-63.40
|
-37.24
|
-38.95
|
34.02
|
-34.67
|
|
Peer Median
|
-30.84
|
--
|
--
|
--
|
--
|
EBIT Margin
-286.42
Lower than Peers by 204.21
Operating profit (EBIT) / Net Sales * 100
|
Company Name
|
TTM
|
Dec-22
|
Dec-21
|
Dec-20
|
Dec-19
|
|---|---|---|---|---|---|
|
Surface Oncology (SURF)
|
-286.42
|
-206.23
|
-2,828.92
|
48.82
|
-373.48
|
|
Peer Median
|
-82.21
|
--
|
--
|
--
|
--
|
Net Margin
-294.71
Lower than Peers by 204.83
Net profit / Total Income (Net sales plus other income) * 100
|
Company Name
|
TTM
|
Dec-22
|
Dec-21
|
Dec-20
|
Dec-19
|
|---|---|---|---|---|---|
|
Surface Oncology (SURF)
|
-294.71
|
-217.68
|
-2,878.02
|
47.03
|
-345.08
|
|
Peer Median
|
-89.88
|
--
|
--
|
--
|
--
|
Cash Profit Margin
0.00
Lower than Peers by 0.00
(Net profit + Depreciation) / Gross Sales * 100
|
Company Name
|
TTM
|
Dec-22
|
Dec-21
|
Dec-20
|
Dec-19
|
|---|---|---|---|---|---|
|
Surface Oncology (SURF)
|
0.00
|
--
|
--
|
--
|
--
|
|
Peer Median
|
0.00
|
--
|
--
|
--
|
--
|
Revenue Growth
-1.79
Lower than Peers by 55.82
Year on year growth in net sales
|
Company Name
|
TTM
|
Dec-22
|
Dec-21
|
Dec-20
|
Dec-19
|
|---|---|---|---|---|---|
|
Surface Oncology (SURF)
|
-1.79
|
10.16
|
-0.98
|
7.21
|
-0.74
|
|
Peer Median
|
54.03
|
--
|
--
|
--
|
--
|
EBIT Growth
-40.84
Lower than Peers by 39.89
Year on year growth in operating profit (EBIT)
|
Company Name
|
TTM
|
Dec-22
|
Dec-21
|
Dec-20
|
Dec-19
|
|---|---|---|---|---|---|
|
Surface Oncology (SURF)
|
-40.84
|
18.61
|
-223.43
|
207.36
|
-526.88
|
|
Peer Median
|
-0.95
|
--
|
--
|
--
|
--
|
Net Profit Growth
-53.69
Lower than Peers by 46.50
Year on year growth in profit after tax
|
Company Name
|
TTM
|
Dec-22
|
Dec-21
|
Dec-20
|
Dec-19
|
|---|---|---|---|---|---|
|
Surface Oncology (SURF)
|
-53.69
|
17.82
|
-233.92
|
211.95
|
-703.46
|
|
Peer Median
|
-7.19
|
--
|
--
|
--
|
--
|
EPS Growth
-19.54
Lower than Peers by 33.97
Year on year growth in earnings per share
|
Company Name
|
TTM
|
Dec-22
|
Dec-21
|
Dec-20
|
Dec-19
|
|---|---|---|---|---|---|
|
Surface Oncology (SURF)
|
-19.54
|
0.37
|
-2.25
|
1.72
|
-6.98
|
|
Peer Median
|
14.43
|
--
|
--
|
--
|
--
|
Book Value Growth
-64.79
Lower than Peers by 54.33
Year on year growth in book value per share
|
Company Name
|
TTM
|
Dec-22
|
Dec-21
|
Dec-20
|
Dec-19
|
|---|---|---|---|---|---|
|
Surface Oncology (SURF)
|
-64.79
|
--
|
--
|
--
|
--
|
|
Peer Median
|
-10.46
|
--
|
--
|
--
|
--
|
Solvency
Debt to Equity
--
--
Total debt / Net worth
|
Company Name
|
TTM
|
Dec-22
|
Dec-21
|
Dec-20
|
Dec-19
|
|---|---|---|---|---|---|
|
Surface Oncology (SURF)
|
--
|
0.60
|
0.48
|
0.32
|
0.44
|
|
Peer Median
|
--
|
--
|
--
|
--
|
--
|
Short term debt to equity ratio
0.19
--
(Short term borrowings / Net worth)
|
Company Name
|
TTM
|
Dec-22
|
Dec-21
|
Dec-20
|
Dec-19
|
|---|---|---|---|---|---|
|
Surface Oncology (SURF)
|
0.19
|
0.06
|
0.05
|
0.04
|
0.05
|
|
Peer Median
|
--
|
--
|
--
|
--
|
--
|
Current Ratio
3.60
Lower than Peers by 2.20
Current Assets / Current Liabilities and Provisions
|
Company Name
|
TTM
|
Dec-22
|
Dec-21
|
Dec-20
|
Dec-19
|
|---|---|---|---|---|---|
|
Surface Oncology (SURF)
|
3.60
|
7.94
|
7.86
|
10.23
|
5.60
|
|
Peer Median
|
5.80
|
--
|
--
|
--
|
--
|
Quick Ratio
3.60
Lower than Peers by 2.09
(Current Assets - Inventory) / Current Liabilities and Provisions
|
Company Name
|
TTM
|
Dec-22
|
Dec-21
|
Dec-20
|
Dec-19
|
|---|---|---|---|---|---|
|
Surface Oncology (SURF)
|
3.60
|
7.95
|
7.90
|
10.37
|
5.62
|
|
Peer Median
|
5.69
|
--
|
--
|
--
|
--
|
Interest Coverage
-17.43
Lower than Peers by 15.35
Earning before interest and taxes (EBIT) / Interest Expenses
|
Company Name
|
TTM
|
Dec-22
|
Dec-21
|
Dec-20
|
Dec-19
|
|---|---|---|---|---|---|
|
Surface Oncology (SURF)
|
-17.43
|
-36.03
|
-30.75
|
27.38
|
--
|
|
Peer Median
|
-2.09
|
--
|
--
|
--
|
--
|
Operating Efficiency
Debtors to sales
--
--
Debtors outstanding / Net Sales * 100
|
Company Name
|
TTM
|
Dec-22
|
Dec-21
|
Dec-20
|
Dec-19
|
|---|---|---|---|---|---|
|
Surface Oncology (SURF)
|
--
|
0.66
|
28.47
|
2.04
|
2.19
|
|
Peer Median
|
18.97
|
--
|
--
|
--
|
--
|
Asset Turnover
0.20
Higher than Peers by 0.14
Sales / Average Total Assets
|
Company Name
|
TTM
|
Dec-22
|
Dec-21
|
Dec-20
|
Dec-19
|
|---|---|---|---|---|---|
|
Surface Oncology (SURF)
|
0.20
|
0.17
|
0.01
|
0.72
|
0.10
|
|
Peer Median
|
0.07
|
--
|
--
|
--
|
--
|
Receivable days
--
--
Average Debtors / Sales * 365
|
Company Name
|
TTM
|
Dec-22
|
Dec-21
|
Dec-20
|
Dec-19
|
|---|---|---|---|---|---|
|
Surface Oncology (SURF)
|
--
|
5.86
|
226.74
|
4.21
|
7.84
|
|
Peer Median
|
--
|
--
|
--
|
--
|
--
|
Inventory Days
--
--
Average Inventory / Sales * 365
|
Company Name
|
TTM
|
Dec-22
|
Dec-21
|
Dec-20
|
Dec-19
|
|---|---|---|---|---|---|
|
Surface Oncology (SURF)
|
--
|
--
|
--
|
--
|
-2.35
|
|
Peer Median
|
--
|
--
|
--
|
--
|
--
|
Payable days
--
--
Average Creditors / Cost of goods sold * 365
|
Company Name
|
TTM
|
Dec-22
|
Dec-21
|
Dec-20
|
Dec-19
|
|---|---|---|---|---|---|
|
Surface Oncology (SURF)
|
--
|
--
|
--
|
--
|
23.81
|
|
Peer Median
|
--
|
--
|
--
|
--
|
--
|
Cash Conversion Cycle
--
--
Receivable Days + Inventory Days - Payable Days
|
Company Name
|
TTM
|
Dec-22
|
Dec-21
|
Dec-20
|
Dec-19
|
|---|---|---|---|---|---|
|
Surface Oncology (SURF)
|
--
|
--
|
--
|
--
|
-18.33
|
|
Peer Median
|
--
|
--
|
--
|
--
|
--
|
Valuation
Price / Earnings
--
--
Current share price divided by earning per share in the last twelve months
|
Company Name
|
TTM
|
Dec-22
|
Dec-21
|
Dec-20
|
Dec-19
|
|---|---|---|---|---|---|
|
Surface Oncology (SURF)
|
--
|
-0.76
|
-2.79
|
6.74
|
-0.99
|
|
Peer Median
|
--
|
--
|
--
|
--
|
--
|
Price / Book Value
0.47
Lower than Peers by 4.88
Current share price divided by book value per share in the latest financial year
|
Company Name
|
TTM
|
Dec-22
|
Dec-21
|
Dec-20
|
Dec-19
|
|---|---|---|---|---|---|
|
Surface Oncology (SURF)
|
0.47
|
0.53
|
1.87
|
2.57
|
0.93
|
|
Peer Median
|
5.35
|
--
|
--
|
--
|
--
|
Dividend Yield
--
--
Dividend per share in the past twelve months divided by current share price
|
Company Name
|
TTM
|
Dec-22
|
Dec-21
|
Dec-20
|
Dec-19
|
|---|---|---|---|---|---|
|
Surface Oncology (SURF)
|
--
|
--
|
--
|
--
|
--
|
|
Peer Median
|
--
|
--
|
--
|
--
|
--
|
EV/EBITDA
0.59
--
Enterprise Value (Current Market Capitalisation + Total Debt - Cash & Equivalents) / Earnings before interest, taxes, depreciation and taxes (EBITDA)
|
Company Name
|
TTM
|
Dec-22
|
Dec-21
|
Dec-20
|
Dec-19
|
|---|---|---|---|---|---|
|
Surface Oncology (SURF)
|
0.59
|
0.32
|
-1.68
|
4.33
|
0.50
|
|
Peer Median
|
--
|
--
|
--
|
--
|
--
|
Market Cap
66
Lower than Peers by 82
Current Share price multiplied by latest total number of shares outstanding
|
Company Name
|
TTM
|
Dec-22
|
Dec-21
|
Dec-20
|
Dec-19
|
|---|---|---|---|---|---|
|
Surface Oncology (SURF)
|
66
|
--
|
--
|
--
|
--
|
|
Peer Median
|
147
|
--
|
--
|
--
|
--
|